Last edition
News about "Orbicular Pharmaceutical Technologies"
Alembic Pharmaceuticals Receives US FDA Approval for Olopatadine Eye Drops
Alembic Pharmaceuticals receives final US FDA approval for its olopatadine hydrochloride ophthalmic solution USP, 0.7 per cent, an OTC treatment for itchy eyes.
Orbicular Pharmaceutical Technologies | 05/11/2026 | By News Bureau
OneSource and Orbicular Receive US FDA Tentative Approval for Generic Semaglutide
OneSource and Orbicular secure US FDA tentative approval for generic semaglutide injection, advancing ANDA filing for Ozempic with manufacturing support from OneSource.
Orbicular Pharmaceutical Technologies | 22/04/2026 | By News Bureau | 331
The partnership among Orbicular Pharmaceutical Technologies, Gland Pharma and Apotex, achieves first ANDA approval with Competitive Generic Therapy designation, gaining six-month exclusivity for complex multivitamin injectable in the United States.
Orbicular Pharmaceutical Technologies | 16/04/2026 | By News Bureau | 407
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy